I have to think that when the FDA approves EDAP for the albatherm hifu for prostate cancer, the share price will have to be more than a few dollars more. What the final price will be is any ones guess, but think of these things first before you sell.
The years and years of trials, The money expending to finance the trials, the many years of research and follow up care in the hospitals, the huge cost of the technology required to put all this together, the costs of all the filing with the government, the marketing of the program to the doctors, the years of lost income from doing all the trials, the millions of dollars of putting all this together and the tremendous work of the EDAP staff over the years. The price should be monumental at the very least from all this work, and make sure the price justifies the means at the end. The ceo has said "IF YOU WAIT TOO LONG, YOU WILL BE SORRY" Hold on to your shares before you sell at cheap prices, just make sure your ok. go edap l
Totally agree And I want to remind everyone EDAP traded at 20 us per share when the company got approved in Europe This time the FDA approval will be big for the company because the US market for prostate cancer treatment worth billions dollar and with FDA approval all other countries will follow So I think my expectation on 120 us price target will be achieved at the end
Why did the price not hold $20s after approval in Europe? Could it because the device was not as successfull as it was initially thought? How did the device improve since the initial approval in Europe? what other additional clinical trials were done since then?
I bought some EDAP based on the potential and cheap market cap but I think we need to understand why stock is so cheap given the enormous market potential before we can talk of $120 US price target.